UNSPSC 51384528: Ibuprofen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H17O2.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM1CE97Z4N, chemically known as hydratropic acid, p-isobutyl-, sodium salt but more generally known as ibuprofen sodium, which bears US NIH Compound Identifier 161696. European Medicines Agency schedules Ibuprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21665.

Most nations, for tariff and trade purposes, schedule ibuprofen sodium under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)[O-].O.O.[NA+].

UNSPSC 51384528 Ibuprofen sodium is a Commodity code that state and local governments use to classify pharmaceutical products, though the recent solicitation activity under this code shows minimal alignment with the nominal product scope. The single recent opportunity tagged to this code is Seminole County, Florida's IFB 60459723LAS, which solicits Naloxone and Safe Drug Deactivation Systems rather than ibuprofen or other NSAIDs — suggesting either a data-entry mismatch in the county's procurement system or a broader pharmaceutical classification that does not reflect the code's intended use. The work being solicited is annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to support community health initiatives, not pain-relief medication. Vendors must comply with drug-free workplace certification, E-Verify requirements, and federal compliance provisions including the Clean Air Act and Federal Water Pollution Control Act, with potential FEMA funding introducing additional regulatory oversight.

The Seminole County opportunity, posted June 30, 2026, with a response deadline of July 26, 2023, represents the only recent state and local activity visible under this code, and the mismatch between the code's nominal pharmaceutical scope and the actual naloxone procurement raises questions about whether this code is used meaningfully in state and local procurement workflows. No other issuing bodies, geographic regions, or representative opportunities appear in recent solicitation records. A business development professional should verify whether this code reflects actual buying patterns within target geographies before investing sourcing effort, as the single available opportunity does not align with the code's stated product category and may indicate either data quality issues or dormant classification usage.